|Bid||116.00 x 800|
|Ask||125.00 x 2200|
|Day's Range||119.40 - 123.32|
|52 Week Range||51.04 - 152.14|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||249.30|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||150.56|
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]
Alphatec Holdings (ATEC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
The “Internet of Things” is already a fairly well-known term, but by next year, I expect it will be a phrase used in every household. The reach of the IoT is massive, which should might have investors asking themselves what are some good Internet of Things stocks to buy? IoT includes the commonly thought of devices like smartphones and televisions, as well as new possibilities such as thermostats, automobiles and even street lights.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Dexcom hit its 52-week high of $152.14 on November 8. In October, Dexcom announced that the US Centers for Medicare & Medicaid Services would cover the new Dexcom G6 Continuous Glucose Monitoring System for Medicare beneficiaries. Dexcom expects to initiate delivery to Medicare beneficiaries in the first half of 2019.
DexCom, Inc. (DXCM) (“DexCom”) announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $100.0 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of DexCom, and will bear interest at a rate of 0.75% per year, payable semi-annually in arrears.
DexCom, Inc. (DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $100 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of DexCom, and interest will be payable semi-annually in arrears.
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Kevin Sayer has been the CEO of DexCom Inc (NASDAQ:DXCM) since 2015. First, this article will compare CEO compensation with compensation at other large companies. Then we’ll look at a Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...
DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, announced an amendment to the Collaboration and License Agreement surrounding the ongoing development efforts between the companies. The revised terms are intended to reinforce the companies’ mutual product development goals, while expanding options for future collaborations. The agreement also accelerates Dexcom’s efforts to advance into the Type 2 diabetes space and improves its future profitability.
Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
DexCom, Inc. ( DXCM), a medical device company, is having one heck of a year. The stock is up over 100% since Jan. 1, but it has even more room to climb, although many investors will look at a high-flying stock like DexCom and assume that it's overbought and destined to collapse from here. Right now, the stock is forming one of my favorite stock patterns: an ascending triangle, which signals that more gains are still to come.
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.